Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000704212 | SCV000833151 | pathogenic | Spastic paraplegia | 2021-03-18 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg624Glyfs*3) in the SACS gene. It is expected to result in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with SACS-related disease. Loss-of-function variants in SACS are known to be pathogenic (PMID: 18465152, 20876471). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV003472245 | SCV004202310 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2023-12-29 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV004997208 | SCV005622140 | pathogenic | not provided | 2024-06-13 | criteria provided, single submitter | clinical testing | This variant is expected to result in the loss of a functional protein. This variant has not been reported in large, multi-ethnic general populations. (http://gnomad.broadinstitute.org) This variant has been identified in at least one individual tested at Athena Diagnostics with clinical features associated with this gene. |